Profiling lecanemab as a treatment option for Alzheimer’s disease-Reference-Cited by-同舟云学术

Profiling lecanemab as a treatment option for Alzheimer’s disease

Published:2024-04-03 Issue:5 Volume:24 Page:433-441
ISSN:1473-7175
Container-title:Expert Review of Neurotherapeutics
language:en
Short-container-title:Expert Review of Neurotherapeutics

Author:

Schiller Emily R.¹^ORCID,Silverglate Bret David²,Grossberg George T.³

Affiliation:

1. Rutgers Robert Wood Johnson Medical School, Clinical Academic Building, New Brunswick, NJ, USA

2. School of Medicine, Department of Psychiatry and Behavioral Neuroscience, Division of Geriatric Psychiatry, Saint Louis University, St. Louis, MO, USA

3. Department of Psychiatry and Behavioral Neuroscience, Division of Geriatric Psychiatry, Geriatric Psychiatry, Saint Louis University School of Medicine, St. Louis, MO, USA

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737175.2024.2333970

Reference37 articles.

1. Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020–2060)

2. US Census Bureau. 2014. National population projections datasets [Internet]. Census.gov. [cited 2023 Sep 18]. Available from: https://www.census.gov/data/datasets/2014/demo/popproj/2014-popproj.html

3. Diagnostic biomarkers of Alzheimer’s disease: A state-of-the-art review

4. NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthesis and Enzymatic Evaluation of a Small Library of Substituted Phenylsulfonamido-Alkyl Sulfamates towards Carbonic Anhydrase II;Molecules;2024-06-25

2. Passive Anti-Amyloid Beta Immunotherapies in Alzheimer’s Disease: From Mechanisms to Therapeutic Impact;Biomedicines;2024-05-15